Iterum Therapeutics plc (ITRM)
After hours:
| Previous Close | 1.2500 |
| Open | 1.2500 |
| Bid | 1.2300 x 300 |
| Ask | 1.2700 x 400 |
| Day's Range | 1.2185 - 1.2900 |
| 52 Week Range | 0.6220 - 2.5000 |
| Volume | |
| Avg. Volume | 185,482 |
| Market Cap | 22.485M |
| Beta (5Y Monthly) | 2.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4300 |
| Earnings Date | Aug 09, 2024 - Aug 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
GlobeNewswireIterum Therapeutics Commences Rights Offering
DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”). Pursuant to the Rights Offering, the Company is distributing, at no charge, subscr
- GlobeNewswire
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Proposed Date for Advisory Committee meeting is September 9, 2024DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA
- GlobeNewswire
Iterum Therapeutics to Present Data at ASM Microbe 2024
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will present a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-17, 2024, in Atlanta, Georgia. Data to be pre
